Neurocrine Biosciences Inc (NBIX)
125.00
+1.71
(+1.39%)
USD |
NASDAQ |
Nov 21, 16:00
123.15
-1.85
(-1.48%)
After-Hours: 20:00
Neurocrine Biosciences Enterprise Value: 11.43B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 11.43B |
| November 20, 2024 | 11.25B |
| November 19, 2024 | 10.83B |
| November 18, 2024 | 10.68B |
| November 15, 2024 | 10.66B |
| November 14, 2024 | 11.21B |
| November 13, 2024 | 11.48B |
| November 12, 2024 | 11.63B |
| November 11, 2024 | 11.65B |
| November 08, 2024 | 11.50B |
| November 07, 2024 | 11.32B |
| November 06, 2024 | 11.46B |
| November 05, 2024 | 11.08B |
| November 04, 2024 | 10.98B |
| November 01, 2024 | 11.15B |
| October 31, 2024 | 10.95B |
| October 30, 2024 | 11.36B |
| October 29, 2024 | 10.54B |
| October 28, 2024 | 10.54B |
| October 25, 2024 | 10.52B |
| October 24, 2024 | 10.47B |
| October 23, 2024 | 10.42B |
| October 22, 2024 | 10.59B |
| October 21, 2024 | 10.57B |
| October 18, 2024 | 10.71B |
| Date | Value |
|---|---|
| October 17, 2024 | 10.76B |
| October 16, 2024 | 10.75B |
| October 15, 2024 | 10.65B |
| October 14, 2024 | 10.56B |
| October 11, 2024 | 10.46B |
| October 10, 2024 | 10.15B |
| October 09, 2024 | 10.07B |
| October 08, 2024 | 10.07B |
| October 07, 2024 | 10.12B |
| October 04, 2024 | 10.31B |
| October 03, 2024 | 10.09B |
| October 02, 2024 | 10.30B |
| October 01, 2024 | 10.32B |
| September 30, 2024 | 10.43B |
| September 27, 2024 | 10.58B |
| September 26, 2024 | 10.67B |
| September 25, 2024 | 10.53B |
| September 24, 2024 | 10.72B |
| September 23, 2024 | 10.85B |
| September 20, 2024 | 10.91B |
| September 19, 2024 | 11.12B |
| September 18, 2024 | 11.06B |
| September 17, 2024 | 11.31B |
| September 16, 2024 | 11.31B |
| September 13, 2024 | 11.31B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.499B
Minimum
Jan 27 2022
14.43B
Maximum
Aug 01 2024
9.748B
Average
9.380B
Median
Oct 22 2021
Enterprise Value Benchmarks
| Repligen Corp | 7.680B |
| West Pharmaceutical Services Inc | 22.95B |
| Bruker Corp | 10.71B |
| The Cooper Companies Inc | 22.42B |
| Integra Lifesciences Holdings Corp | 3.304B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 129.80M |
| Revenue (Quarterly) | 622.10M |
| Total Expenses (Quarterly) | 437.30M |
| EPS Diluted (Quarterly) | 1.24 |
| Gross Profit Margin (Quarterly) | 98.71% |
| Profit Margin (Quarterly) | 20.86% |
| Earnings Yield | 2.98% |
| Operating Earnings Yield | 4.55% |
| Normalized Earnings Yield | 2.531 |